Astrazeneca (AZN) Liabilities and Shareholders Equity (2009 - 2026)

Astrazeneca's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $114.0 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 7.31% year-over-year to $114.0 billion; the TTM figure through Mar 2026 stood at $455.0 billion (up 8.44% YoY), while the FY2025 annual figure was $114.1 billion, up 9.65% from the prior year.
• Liabilities and Shareholders Equity was $114.0 billion for Q1 2026 at Astrazeneca, roughly flat from $114.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $114.5 billion in Q3 2025 to a low of $313.0 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $97.3 billion across 5 years, with a median of $102.3 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 92672.12% in 2022, then slumped 99.68% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $96.5 billion in 2022, then plunged by 99.68% to $313.0 million in 2023, then soared by 33138.02% to $104.0 billion in 2024, then gained by 9.65% to $114.1 billion in 2025, then fell by 0.05% to $114.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $114.0 billion (Q1 2026), $114.1 billion (Q4 2025), and $114.5 billion (Q3 2025), per Business Quant data.